PathoGenetix Picks Sagentia to Develop Commercial-Scale Microbial Detection System | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sagentia said today that it has been picked by PathoGenetix to develop a commercial scale system for rapid microbial detection and strain typing based on the Woburn, Mass.-based firm's Genome Sequence Scanning technology.

PathoGenetix plans to launch the system's first commercial application, for the research market, in late 2012.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.